551 related articles for article (PubMed ID: 16717135)
1. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.
Chen L; Sung SS; Yip ML; Lawrence HR; Ren Y; Guida WC; Sebti SM; Lawrence NJ; Wu J
Mol Pharmacol; 2006 Aug; 70(2):562-70. PubMed ID: 16717135
[TBL] [Abstract][Full Text] [Related]
2. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
3. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
4. Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor.
Cunnick JM; Dorsey JF; Munoz-Antonia T; Mei L; Wu J
J Biol Chem; 2000 May; 275(18):13842-8. PubMed ID: 10788507
[TBL] [Abstract][Full Text] [Related]
5. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor.
Yart A; Laffargue M; Mayeux P; Chretien S; Peres C; Tonks N; Roche S; Payrastre B; Chap H; Raynal P
J Biol Chem; 2001 Mar; 276(12):8856-64. PubMed ID: 11134009
[TBL] [Abstract][Full Text] [Related]
6. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor.
Meng S; Chen Z; Munoz-Antonia T; Wu J
Biochem J; 2005 Oct; 391(Pt 1):143-51. PubMed ID: 15952937
[TBL] [Abstract][Full Text] [Related]
7. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2.
Cunnick JM; Mei L; Doupnik CA; Wu J
J Biol Chem; 2001 Jun; 276(26):24380-7. PubMed ID: 11323411
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.
Chen L; Pernazza D; Scott LM; Lawrence HR; Ren Y; Luo Y; Wu X; Sung SS; Guida WC; Sebti SM; Lawrence NJ; Wu J
Biochem Pharmacol; 2010 Sep; 80(6):801-10. PubMed ID: 20510203
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2.
Cunnick JM; Meng S; Ren Y; Desponts C; Wang HG; Djeu JY; Wu J
J Biol Chem; 2002 Mar; 277(11):9498-504. PubMed ID: 11779868
[TBL] [Abstract][Full Text] [Related]
11. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26).
Song M; Park JE; Park SG; Lee DH; Choi HK; Park BC; Ryu SE; Kim JH; Cho S
Biochem Biophys Res Commun; 2009 Apr; 381(4):491-5. PubMed ID: 19233143
[TBL] [Abstract][Full Text] [Related]
12. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor.
Ren Y; Meng S; Mei L; Zhao ZJ; Jove R; Wu J
J Biol Chem; 2004 Feb; 279(9):8497-505. PubMed ID: 14665621
[TBL] [Abstract][Full Text] [Related]
13. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins.
Krejci P; Masri B; Salazar L; Farrington-Rock C; Prats H; Thompson LM; Wilcox WR
J Biol Chem; 2007 Feb; 282(5):2929-36. PubMed ID: 17145761
[TBL] [Abstract][Full Text] [Related]
14. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif.
Pulido R; Zúñiga A; Ullrich A
EMBO J; 1998 Dec; 17(24):7337-50. PubMed ID: 9857190
[TBL] [Abstract][Full Text] [Related]
15. Structure of the hematopoietic tyrosine phosphatase (HePTP) catalytic domain: structure of a KIM phosphatase with phosphate bound at the active site.
Mustelin T; Tautz L; Page R
J Mol Biol; 2005 Nov; 354(1):150-63. PubMed ID: 16226275
[TBL] [Abstract][Full Text] [Related]
16. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Krenz M; Yutzey KE; Robbins J
Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
[TBL] [Abstract][Full Text] [Related]
17. The protein kinase C inhibitor Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] potentiates agonist-induced mitogen-activated protein kinase activation through tyrosine phosphorylation of the epidermal growth factor receptor.
Shah BH; Olivares-Reyes JA; Catt KJ
Mol Pharmacol; 2005 Jan; 67(1):184-94. PubMed ID: 15465928
[TBL] [Abstract][Full Text] [Related]
18. Interaction of scaffolding adaptor protein Gab1 with tyrosine phosphatase SHP2 negatively regulates IGF-I-dependent myogenic differentiation via the ERK1/2 signaling pathway.
Koyama T; Nakaoka Y; Fujio Y; Hirota H; Nishida K; Sugiyama S; Okamoto K; Yamauchi-Takihara K; Yoshimura M; Mochizuki S; Hori M; Hirano T; Mochizuki N
J Biol Chem; 2008 Aug; 283(35):24234-44. PubMed ID: 18577518
[TBL] [Abstract][Full Text] [Related]
19. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
20. EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR.
Furcht CM; Buonato JM; Lazzara MJ
Sci Signal; 2015 May; 8(376):ra46. PubMed ID: 25969544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
